GlassScriptPhysician profile
Edward J Collins
NPI 1265533475
$5,465.58
in general payments reported to CMS, 2019-2025
31 companies · $24.33 in 2025
The $24.33 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $441 · 2021: $698 · 2022: $1,831 · 2023: $1,413 · 2024: $361 · 2025: $24.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $1,038.53 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $941.10 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $751.69 | 2019-2024 | Myrbetriq, Veozah |
| Abbvie INC. | $535.80 | 2019-2024 | Lupron Depot |
| Janssen Biotech, INC. | $315.47 | 2019-2023 | Erleada |
| Dornier Medtech America, INC | $204.57 | 2022 | |
| Boston Scientific Corporation | $177.82 | 2019-2020 | |
| Procept Biorobotics Corporation | $170.16 | 2022 | |
| Dendreon Pharmaceuticals LLC | $160.27 | 2019 | |
| Abiomed | $157.69 | 2024 | Impella |
| Antares Pharma, INC. | $141.01 | 2020-2021 | |
| Neotract INC. | $123.98 | 2020 | |
| Blue Earth Diagnostics | $106.31 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.03 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $63.58 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $58.99 | 2020-2023 | |
| Endo Pharmaceuticals INC. | $58.75 | 2019-2023 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $55.40 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $44.72 | 2019 | |
| Myovant Sciences INC. | $29.71 | 2021 | |
| Accord Healthcare, INC. | $28.69 | 2023 | |
| Coloplast Corp | $27.02 | 2021 | |
| Ambu INC. | $24.33 | 2025 | |
| Angiodynamics, INC. | $24.25 | 2019 | |
| Dentsply Ih INC. | $20.21 | 2019 | |
| Allergan, INC. | $19.34 | 2022 | |
| Olympus America INC. | $18.35 | 2022 | |
| Photocure INC | $18.04 | 2022 | |
| Travere Therapeutics, INC. | $16.50 | 2019 | |
| Acerus Pharmaceuticals Corporation | $15.81 | 2022 | |
| Sagent Pharmaceuticals | $15.46 | 2023 | Glydo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.